Literature DB >> 33414132

The State of Melanoma: Emergent Challenges and Opportunities.

Michael B Atkins1, Clara Curiel-Lewandrowski2, David E Fisher3, Susan M Swetter4, Hensin Tsao5, Julio A Aguirre-Ghiso6, Maria S Soengas7, Ashani T Weeraratna8, Keith T Flaherty5, Meenhard Herlyn9, Jeffrey A Sosman10, Hussein A Tawbi11, Anna C Pavlick12, Pamela B Cassidy13, Sunandana Chandra10, Paul B Chapman14, Adil Daud15, Zeynep Eroglu16, Laura K Ferris17, Bernard A Fox18, Jeffrey E Gershenwald19, Geoffrey T Gibney20, Douglas Grossman21, Brent A Hanks22, Douglas Hanniford23, Eva Hernando23, Joanne M Jeter24, Douglas B Johnson25, Samir N Khleif26, John M Kirkwood27, Sancy A Leachman13, Darren Mays28, Kelly C Nelson29, Vernon K Sondak16, Ryan J Sullivan5, Glenn Merlino.   

Abstract

Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33414132      PMCID: PMC8127340          DOI: 10.1158/1078-0432.CCR-20-4092

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  62 in total

1.  Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.

Authors:  Su Y Lim; Jenny H Lee; Tuba N Gide; Alexander M Menzies; Alexander Guminski; Matteo S Carlino; Edmond J Breen; Jean Y H Yang; Shila Ghazanfar; Richard F Kefford; Richard A Scolyer; Georgina V Long; Helen Rizos
Journal:  Clin Cancer Res       Date:  2018-11-08       Impact factor: 12.531

Review 2.  Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

Authors:  David McDermott; Celeste Lebbé; F Stephen Hodi; Michele Maio; Jeffrey S Weber; Jedd D Wolchok; John A Thompson; Charles M Balch
Journal:  Cancer Treat Rev       Date:  2014-07-07       Impact factor: 12.111

3.  The benefits of immunotherapy combinations.

Authors:  Charles Schmidt
Journal:  Nature       Date:  2017-12-21       Impact factor: 49.962

4.  Prevalence of Indoor Tanning and Association With Sunburn Among Youth in the United States.

Authors:  Gery P Guy; Zahava Berkowitz; Sherry Everett Jones; Meg Watson; Lisa C Richardson
Journal:  JAMA Dermatol       Date:  2017-05-01       Impact factor: 10.282

Review 5.  MoleMapper: an application for crowdsourcing mole images to advance melanoma early-detection research.

Authors:  Tracy Petrie; Ravikant Samatham; Shaun M Goodyear; Dan E Webster; Sancy A Leachman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

6.  Trends in Melanoma Incidence Among Non-Hispanic Whites in the United States, 2005 to 2014.

Authors:  Dawn M Holman; MaryBeth B Freeman; Meredith L Shoemaker
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

7.  Skin β-endorphin mediates addiction to UV light.

Authors:  Gillian L Fell; Kathleen C Robinson; Jianren Mao; Clifford J Woolf; David E Fisher
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

8.  Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo.

Authors:  Rashi Malesu; Andrew J Martin; J Guy Lyons; Richard A Scolyer; Andrew C Chen; Catriona A McKenzie; Jason Madore; Gary M Halliday; Diona L Damian
Journal:  Photochem Photobiol Sci       Date:  2020-02-19       Impact factor: 3.982

9.  A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes.

Authors:  Laura K Ferris; Melissa I Saul; Yan Lin; Fei Ding; Martin A Weinstock; Alan C Geller; Jian-Min Yuan; Erica Neuren; Spandana Maddukuri; Francis X Solano; John M Kirkwood
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

10.  Consensus recommendations for the use of noninvasive melanoma detection techniques based on results of an international Delphi process.

Authors:  Reid A Waldman; Jane M Grant-Kels; Clara N Curiel; Julia Curtis; Salvador González Rodríguez; Shasa Hu; Philip Kerr; Ashfaq Marghoob; Orit Markowitz; Giovanni Pellacani; Harold Rabinovitz; Babar Rao; Alon Scope; Jennifer A Stein; Susan M Swetter
Journal:  J Am Acad Dermatol       Date:  2019-09-26       Impact factor: 11.527

View more
  8 in total

1.  Cell position matters in tumour development.

Authors:  Jean-Christophe Marine; María S Soengas
Journal:  Nature       Date:  2022-04       Impact factor: 49.962

2.  A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.

Authors:  An-An Li; Fan Li; Min Lan; Yu Zhang; Dong Xie; Mei-Ying Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-10       Impact factor: 4.322

3.  Low-Dose Albendazole Inhibits Epithelial-Mesenchymal Transition of Melanoma Cells by Enhancing Phosphorylated GSK-3β/Tyr216 Accumulation.

Authors:  Zhiqiang He; Shun Lei; Fucheng Liang; Liuchang Tan; Weinan Zhang; Luoyingzi Xie; Hong Zheng; Yuangang Lu
Journal:  J Oncol       Date:  2021-12-20       Impact factor: 4.375

4.  Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.

Authors:  David Olmeda; Daniela Cerezo-Wallis; Cynthia Mucientes; Tonantzin G Calvo; Estela Cañón; Direna Alonso-Curbelo; Nuria Ibarz; Javier Muñoz; José L Rodriguez-Peralto; Pablo Ortiz-Romero; Sagrario Ortega; María S Soengas
Journal:  EMBO Mol Med       Date:  2021-11-11       Impact factor: 12.137

5.  Deciphering the Functional Role of RIPK4 in Melanoma.

Authors:  Ewelina Madej; Damian Ryszawy; Anna A Brożyna; Malgorzata Czyz; Jaroslaw Czyz; Agnieszka Wolnicka-Glubisz
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

6.  Loxl3 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival.

Authors:  Alberto Vázquez-Naharro; José Bustos-Tauler; Alfredo Floristán; Lourdes Yuste; Sara S Oltra; Antònia Vinyals; Gema Moreno-Bueno; Àngels Fabra; Francisco Portillo; Amparo Cano; Patricia G Santamaría
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

7.  Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma.

Authors:  Saul Carcamo; Christie B Nguyen; Elena Grossi; Dan Filipescu; Aktan Alpsoy; Alisha Dhiman; Dan Sun; Sonali Narang; Jochen Imig; Tiphaine C Martin; Ramon Parsons; Iannis Aifantis; Aristotelis Tsirigos; Julio A Aguirre-Ghiso; Emily C Dykhuizen; Dan Hasson; Emily Bernstein
Journal:  Cell Rep       Date:  2022-04-05       Impact factor: 9.995

8.  Expression Patterns of Necroptosis-Related Genes: Predicting Prognosis and Immunotherapeutic Effects in Cutaneous Melanoma.

Authors:  Dong Dong; Wei Wang; Heng Wang; Liang Chen; Tianyi Liu
Journal:  J Oncol       Date:  2022-07-14       Impact factor: 4.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.